

## **Engagement Report for Clinical Commissioning Policy Statements**

|  | 4005   |
|--|--|
| Unique<br>Reference<br>Number  | 1605   |
| Policy Title   | Bendamustine with rituximab for first line treatment of advanced indolent non-Hodgkin's lymphoma   |
| Accountable<br>Commissioner  | Lisa Jordan  |
| Clinical<br>Reference<br>Group   | Chemotherapy   |
|  |  |
| Which<br>stakeholders<br>were contacted<br>to be involved<br>in policy<br>development?   | A policy working group was established as per NHS England<br>policy, clinical and PPV reps were members of the chemotherapy<br>CRG.<br>All CRG members and registered stakeholders were sent copies of<br>the draft policy documents for comment.  |
| Identify the<br>relevant Royal<br>College or<br>Professional<br>Society to the<br>policy and<br>indicate how<br>they have been<br>involved | All of the relevant Royal Colleges and professional societies have<br>membership on the CRG. These include:<br>British Oncology Pharmacy Association<br>Royal College of Pathologists<br>British Society for Haematology<br>A representative for each group was sent all policy documents and<br>given the opportunity to comment. |
| Which<br>stakeholders<br>have actually<br>been involved?   | CRG members and a response from one registered stakeholder regarding draft documents.  |
| Explain reason<br>if there is any<br>difference from<br>previous<br>question   | No response from other stakeholders  |
| Identify any particular  | None   |

| stakeholder<br>organisations<br>that may be key<br>to the policy<br>development<br>that you have<br>approached<br>that have yet to<br>be engaged.<br>Indicate why? |   |
|--|---|
| How have<br>stakeholders<br>been involved?<br>What<br>engagement<br>methods have<br>been used?   | As per policy development process all CRG members and CRG registered stakeholders have been emailed draft policy documents for comment.   |
| What has<br>happened or<br>changed as a<br>result of their<br>input?   | No changes have been made to the policy proposition. Reference<br>to a statement from Astellas regarding the safety of bendamustine<br>when used in non-approved combination treatments has been<br>added. The PWG did not feel that this information was sufficient to<br>change the conclusions of the evidence review but that clinicians<br>should be made aware of the risk of infections. |
| How are<br>stakeholders<br>being kept<br>informed of<br>progress with<br>policy<br>development as<br>a result of their<br>input?                                   | Communication will be according to NHS England policy development process   |
| What level of<br>wider public<br>consultation is<br>recommended<br>by the CRG for<br>the NPOC<br>Board to agree<br>as a result of<br>stakeholder<br>involvement?   | The CRG recommends 30 days public consultation based on the level of stakeholder response and the nature of the policy.   |